Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Viking Therapeutics reported Q3 2026 results with a net loss of $183.2 million ($1.55/share) versus $90.8 million ($0.81/share) a year ago, driven by a doubling of R&D spend to $166.8 million as Phase 3 programs scale. The pipeline advanced on multiple fronts: VANQUISH Phase 3 trials for subcutaneous VK2735 remain on track for 2027 completion, SUNRISE oral Phase 3 trials are now underway, and Part 1 of the maintenance dosing study showed 83-97% weight-loss retention on less-frequent dosing with continued weight loss to ~22% on weekly dosing.
Key figures
- Revenue
- 0
- Guidance
- VANQUISH Phase 3 completion expected 2027; VK3019 MAD study to initiate 1Q27; maintenance Part 2 results in 2027
- Net loss q3
- 183200000
- Cash position
- 960000000
- Ga expense q3
- 20300000
- Rd expense q3
- 166800000
- Cash prior year end
- 706000000
- Net loss nine months
- 469500000
- Net loss prior year q3
- 90800000
- Gross proceeds offering
- 575000000
- Maintenance weight retained eow
- 83% to 97%
- Ventura week21 weight loss range
- approximately 16% to 19%
- Maintenance weight retained monthly
- 82% to 90%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.